Faricimab inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways which may extend treatment durability beyond current anti-VEGF therapies for diabetic macular edema (DME). It was a pleasure to speak with Dr Jennifer Lim (University of Illinois Chicago, IL, USA) around the treat-and-extend regimen with faricimab in the YOSEMITE/RHINE (NCT03622580/NCT03622593) trials and the […]

Diabetic macular edema is characterised by exudative fluid accumulation in the macula and is the most common form of sight-threatening retinopathy in people with diabetes affecting one in 15 people with diabetes. Intraocular pharmacotherapy with anti-VEGF agents is the standard of care. It was a pleasure to speak with Dr Jennifer Lim (University of Illinois […]

The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]

Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]

The RESTORE trial (NCT04945772) is a phase 2b randomized, sham-controlled, multi-centre, multi-dose, double-masked clinical trial evaluating the efficacy and safety of MCO-010 optogenetic therapy in adults with retinitis pigmentosa. MCO-010 is an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical […]

Retinitis pigmentosa is an inherited retinal dystrophy (IRD) caused by the loss of photoreceptors and characterized by retinal pigment deposits visible on fundus examination. Retinitis pigmentosa is the most common group of IRD. It was a pleasure to speak with Prof. David Boyer (Retina Vitreous Associates Medical Group, Los Angeles, CA, USA) around Retinitis Pigmentosa […]

The YOSEMITE/RHINE (NCT03622580/NCT03622593) trials were double-masked, active comparator–controlled, phase 3 trials investigating the efficacy, safety, and durability of faricimab 6.0 mg versus aflibercept 2.0 mg in patients with diabetic macular edema (DME). It was a pleasure to speak with Dr Andreas Pollreisz (Medical University of Vienna, Austria) around the YOSEMITE/RHINE trials as well as their […]

Diabetic macular edema is characterised by exudative fluid accumulation in the macula and is the most common form of sight-threatening retinopathy in people with diabetes affecting one in 15 people with diabetes. Intraocular pharmacotherapy with anti-VEGF agents is the standard of care. It was a pleasure to speak with Dr Andreas Pollreisz (Medical University of […]

We were delighted to speak with Dr Raymond Douglas (Cedars-Sinai Medical Center, Los Angeles, CA, USA) about advances in treatment options for patients with thyroid eye disease. Questions:     What have been the most important recent treatment advances in thyroid eye disease (TED)? (0:18)     What factors should affect treatment decisions in TED? […]